回顾过去以推动未来:历史临床试验数据与机器学习能否在预期未来价值评估中改变参与者招募
本文提出结合历史临床试验数据与真实世界数据,利用机器学习聚类及贝叶斯聚类框架识别最优基线特征分布,以改善招募策略的通用性与以患者为中心的设计。
要点
- 试验人群基线特征与实际人群不符会限制结果外推及HTA评估。
- 机器学习聚类结合真实世界数据可优化基线特征分布与招募策略。
核心结论
- 结合既往试验数据与真实世界数据并应用机器学习技术,可更有效捕捉人群异质性并设计更具通用性、以患者为中心的招募策略。
研究设计与样本
- 本文为概念性论文,提出利用历史临床试验数据与真实世界数据结合机器学习聚类方法优化试验人群基线特征分布的方法学框架。
主要发现
- 试验人群与真实世界患者在基线特征(如年龄、合并症、疾病严重程度)上显著不同时,结果对常规临床实践的适用性可能受限。
- 真实世界数据可帮助评估和校准临床试验人群的代表性,但存在关键亚组代表性不足和生物标志物数据缺失等局限。
- 历史临床试验数据可提供基线特征分布和招募模式的信息,并支持更可靠的比较效果估计。
- 机器学习聚类方法可识别最优基线特征分布,贝叶斯聚类框架纳入真实世界数据可进一步细化估计并与真实世界流行病学更好对齐。
临床怎么用
- 作者提出,研究人员可结合既往试验数据与真实世界数据并应用机器学习技术,更有效捕捉人群异质性并设计更具通用性、以患者为中心的招募策略。
局限性
- 真实世界数据存在关键亚组代表性不足和生物标志物数据缺失等局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug development is an expensive endeavor, with costs averaging $879.3 million and only 14.3% of them ultimately securing regulatory approval. One fundamental challenge is ensuring that the enrolled patient population in a clinical trial accurately reflects the broader target population's baseline characteristics (BCx). This concern ties directly to the generalizability of study findings beyond the trial setting. If the trial population differs significantly from real-world patients in terms of BCx (e.g., age, comorbidities, disease severity), the applicability of the results to routine clinical practice may be limited. Both regulatory agencies and health technology assessment (HTA) bodies may question the generalizability and transportability of trial results to real-world settings. HTA bodies may further require robust comparative effectiveness estimates, which necessitate alignment with the patient populations of previous studies. Real-world data (RWD) can help assess and calibrate the representativeness of clinical trial populations, though limitations persist, including underrepresentation of key subgroups and missing biomarker data. Historical clinical trial data can offer valuable insights into BCx distributions and recruitment patterns, as well as enable more reliable estimates of comparative effectiveness. Machine learning (ML) can enhance this process by leveraging clustering methods to identify optimal BCx distributions, thereby improving trial generalizability. Moreover, Bayesian clustering frameworks that incorporate RWD can further refine these estimates, ensuring better alignment with real-world epidemiology. This paper proposes that, by combining insights from prior trials with RWD using ML techniques, researchers can more effectively capture population heterogeneity and design more generalizable, patient-centric recruitment strategies.
引用
- Paul Choudhury S, Dutta Majumdar A, Mahon R, et al. Looking back to move forward: can historical clinical trial data and machine learning drive change in participant recruitment in anticipation of future value assessments? Trials. 2025. PMID: 41094484. doi:10.1186/s13063-025-09160-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。